This positive Phase 3 data is a strong catalyst for Genmab, supporting epcoritamab's label expansion into a large DLBCL market. Traders should monitor regulatory submissions and upcoming medical meeting presentations for full data. The strong hazard ratios suggest a high likelihood of approval, which could drive upside. Watch for competitor responses from CAR-T and other bispecifics.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 30 $27.47entry
- T+1 · 5mo ago +0.62%α +0.75% · $27.64
- T+5 · 4mo ago +1.97%α +1.36% · $28.01
- T+20 · 4mo ago +4.84%α +5.87% · $28.80
- T+60 · 8w ago +26.50%α +23.68% · $34.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab announced positive topline Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, meeting the primary endpoint with statistically significant improvement in progression-free survival (PFS). The risk of disease progression and death was reduced by 60% (HR 0.40) and 56% (HR 0.44) under different censoring rules, with safety consistent with individual agents. This is a major clinical win that supports label expansion and strengthens epcoritamab's position as a core therapy in B-cell malignancies.
Key Facts
- Phase 3 EPCORE DLBCL-4 trial met primary endpoint with statistically significant improvement in PFS
- Risk reduction of 60% (HR 0.40, 95% CI 0.30-0.55, p<0.0001) in the U.S. and 56% (HR 0.44, 95% CI 0.33-0.60, p<0.0001) outside the U.S.
- Safety profile of epcoritamab plus lenalidomide consistent with known profiles of individual agents
- Genmab and AbbVie will engage global regulatory authorities for potential label expansion
- Epcoritamab is already approved in >65 territories for certain lymphoma indications
Financial Impact
Potential label expansion in RR DLBCL could significantly increase epcoritamab revenue; no specific financial guidance provided in the filing.
Risk Factors
- Regulatory approval is not guaranteed; full data and safety details are pending
- Competition from CAR-T therapies and other bispecific antibodies in DLBCL
- Potential for unforeseen safety signals in larger patient populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000100 |
| Document: gmab_20260629x6k.htm | 0001434265-26-000100 |
| Document: 0001434265-26-000100-index-headers.html | 0001434265-26-000100 |
| Document: 0001434265-26-000100-index.html | 0001434265-26-000100 |
| Document: 0001434265-26-000100.txt | 0001434265-26-000100 |
Track record
31 reports on GMAB
2 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers